OPRM1 and non-small cell lung carcinoma: μ-Opioid receptors, the product of the OPRM1 gene, have been demonstrated on several cancer cell lines including breast cancer, non-small cell lung cancer, adenocarcinoma and gastric carcinoma [19–21].